Related Experiment Video
Updated: Jul 20, 2026
Investigations on the Ga(III) Complex of EOB-DTPA and Its 68Ga Radiolabeled Analogue
Published on: August 17, 2016
Preclinical characterization of anticancer gallium(III) complexes: solubility, stability, lipophilicity and binding
Alexander V Rudnev1, Lidia S Foteeva, Christian Kowol
1Vernadsky Institute of Geochemistry and Analytical Chemistry, Russian Academy of Sciences, Kosygin St. 19, 119991 Moscow, Russia.
Abstract:
The discovery and development of gallium(III) complexes capable of inhibiting tumor growth is an emerging area of anticancer drug research. A range of novel gallium coordination compounds with established cytotoxic efficacy have been characterized in terms of desirable chemical and biochemical properties and compared with tris(8-quinolinolato)gallium(III) (KP46), a lead anticancer gallium-based candidate that successfully finished phase I clinical trials (under the name FFC11), showing activity against renal cell cancer. In view of probable oral administration, drug-like parameters, such as solubility in water, saline and 0.5% dimethyl sulfoxide, stability against hydrolysis, measured as the rate constant of hydrolytic degradation in water or physiological buffer using a capillary zone electrophoresis (CZE) assay, and the octanol-water partition coefficient (logP) providing a rational estimate of a drug's lipophilicity, have been evaluated and compared. The differences in bioavailability characteristics between different complexes were discussed within the formalism of structure-activity relationships. The reactivity toward major serum transport proteins, albumin and transferrin, was also assayed in order to elucidate the drug's distribution pathway after intestinal absorption. According to the values of apparent binding rate constants determined by CZE, both KP46 and bis(2-acetylpyridine-4,4-dimethyl-3-thiosemicarbazonato-N,N,S)gallium(III) tetrachlorogallate(III) (KP1089) bind to transferrin faster than to albumin. This implies that transferrin would rather mediate the accumulation of gallium antineoplastic agents in solid tumors. A tendency of being faster converted into the protein-bound form found for KP1089 (due possibly to non-covalent binding) seems complementary to its greater in vitro antiproliferative activity.
Insights
Novel gallium compounds show promise as anticancer drugs. These agents target tumors by binding to transferrin, a protein that facilitates drug delivery, potentially enhancing efficacy.
Area of Science:
- Medicinal Chemistry
- Oncology
- Drug Discovery
Background:
- Gallium(III) complexes are an emerging class of anticancer agents.
- Tris(8-quinolinolato)gallium(III) (KP46) is a lead candidate that completed Phase I clinical trials for renal cell cancer.
Purpose of the Study:
- To characterize novel gallium coordination compounds for anticancer drug research.
- To compare drug-like parameters and bioavailability characteristics of different gallium complexes.
- To investigate the interaction of gallium complexes with serum transport proteins (albumin and transferrin).
Main Methods:
- Evaluation of solubility, hydrolytic stability (using capillary zone electrophoresis - CZE), and lipophilicity (logP).
- Assay of reactivity toward albumin and transferrin using CZE to determine binding rate constants.
- Structure-activity relationship analysis of bioavailability differences.
Main Results:
- Novel gallium complexes were characterized and compared to KP46.
- Drug-like parameters including solubility and stability were assessed.
- Both KP46 and bis(2-acetylpyridine-4,4-dimethyl-3-thiosemicarbazonato-N,N,S)gallium(III) tetrachlorogallate(III) (KP1089) exhibited faster binding to transferrin than albumin.
- KP1089 showed a greater tendency for faster conversion into a protein-bound form, correlating with higher in vitro antiproliferative activity.
Conclusions:
- Gallium complexes demonstrate potential as orally administered anticancer agents.
- Transferrin is implicated as a key mediator for gallium antineoplastic agent accumulation in solid tumors.
- KP1089's properties suggest it may be a promising candidate for further anticancer drug development.
